Asthma is a chronic inflammatory disease of the airway that is characterize
d by cellular infiltration and activation. These processes are induced by o
verexpression of chemokines and cytokines, such as eotaxin, IL-1 beta and G
M-CSF. These mediators are downstream targets for the transcription factors
activator protein-1 (AP-1) and nuclear factor-kappaB (NF-kappaB), which co
ntrol the expression of most immunomodulatory genes and whose activity and
expression are elevated in asthma. Glucocorticoids are the most effective a
nti-inflammatory drugs used in the treatment of chronic inflammatory diseas
es such as asthma. They act by binding to a specific glucocorticoid recepto
r (GR) that on activation translocates to the nucleus and either increases
(transactivates) or decreases (transrepresses) the expression of responsive
genes. Transrepression is the major mechanism of glucocorticoid action in
inhibiting inflammatory gene expression. Thus, the ability of the transcipt
ion factors AP-1 and NF-kappaB to induce gene transcription is attenuated b
y GR. Although only 5-10% of asthmatic subjects are glucocorticoid-insensit
ive, these subjects account for over 50% of the health-care costs for asthm
a (> $6 billion per annum). Examining these patients also gives an insight
into important aspects of glucocorticoid action in controlling inflammation
and into the development of potential new drugs. Biochemical and genomic s
tudies have indicated abnormal induction of the c-Jun N-terminal kinase (JN
K) pathway in some of these patients. The ability of most patients to respo
nd to dexamethasone with induction of histone acetylation correlated with n
uclear translocation of GR. However, a subgroup of these patients had an in
ability to correctly interact with the basal transcription complex in spite
of high levels of nuclear GR. This suggests that cross-talk between pro- a
nd anti-inflammatory transcription factors may modulate activation of the t
ranscriptional complex and thereby reduce steroid actions.